彩盈彩票

NEWS more +

  • Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

  • China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

  • Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA

友情链接:极速赛车pk10  快乐赛车彩票  pk10赛车  pk10赛车  幸福彩票  豪享彩票官网  快乐飞艇计划官网  at彩票官网  趣彩彩票平台  pk赛车彩票官网